Citi has maintained its “sell” rating on the stock with a price target of ₹990. It said that the Revlimid generic-led drag will be tough to offset as Dr. Reddy’s complex pipeline is surprising negatively.
Citi has maintained its “sell” rating on the stock with a price target of ₹990. It said that the Revlimid generic-led drag will be tough to offset as Dr. Reddy’s complex pipeline is surprising negatively.